ISTA allergy drug heading in the right direction

Article

ISTA Pharmaceuticals has released promising preliminary results of a Phase II/III clinical study of its treatment for allergic conjunctivitis, bepotastine.

ISTA Pharmaceuticals has released promising preliminary results of a Phase II/III clinical study of its treatment for allergic conjunctivitis, bepotastine.

The study evaluated two concentrations, each dosed once and twice daily. Primary endpoints included efficacy in treating ocular itching and redness. Preliminary results demonstrate that both concentrations were highly statistically significant in the reduction of ocular itching, when dosed twice a day and in one concentration when dosed once a day. Both concentrations and dosing regimens also demonstrated highly statistically significant differences in the rapidity of response and the improvement in total nasal symptoms versus placebo. Evaluation of the second primary endpoint, ocular redness, showed a trend towards clinical significance but did not achieve statistical significance.

ISTA now plans to complete analysis of the data and discuss the results with the FDA to determine whether any further clinical studies are required before submitting a New Drug Application.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
At this year's ESCRS meeting, we asked presenters and attendees, 'What do yoou wish you'd known earlier in your ophthalmology career?'
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.